検索結果 - David Magalashvili

  • 検索結果 1 - 7 結果 / 7
結果の絞り込み
  1. 1
    Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

    Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies 著者: Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Shlomo Flechter, Rina Falb, Michael Gurevich

    出版事項 2021
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  2. 2
    Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

    Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod 著者: Anat Achiron, Mathilda Mandel, Michael Gurevich, Sapir Dreyer-Alster, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Gil Harari, Shlomo Flechter, Rina Falb

    出版事項 2022
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  3. 3
    Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

    Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study 著者: Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, Mark Dolev, Shay Menascu, David Magalashvili, Shlomo Flechter, Uri Givon, Diana Guber, Polina Sonis, Rina Zilkha‐Falb, Michael Gurevich

    出版事項 2021
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  4. 4
    Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study

    Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study 著者: Anat Achiron, Joab Chapman, David Magalashvili, Mark Dolev, Mor Lavie, Eran Bercovich, Michael Polliack, Glen M. Doniger, Yael Stern, O. Khilkevich, Shay Menascu, Hararai Gil, Michael Gurevich, Yoram Barak

    出版事項 2013
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  5. 5
    COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

    COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 著者: Anat Achiron, Mark Dolev, Shay Menascu, Daniela-Noa Zohar, Sapir Dreyer-Alster, Shmuel Miron, Emanuel Shirbint, David Magalashvili, Shlomo Flechter, Uri Givon, Diana Guber, Yael Stern, Michael Polliack, Rina Falb, Michael Gurevich

    出版事項 2021
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  6. 6
    COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

    COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose 著者: Sapir Dreyer-Alster, Shay Menascu, Mathilda Mandel, Emanuel Shirbint, David Magalashvili, Mark Dolev, Shlomo Flechter, Uri Givon, Diana Guber, Yael Stern, Shmuel Miron, Michael Polliack, Rina Falb, Polina Sonis, Michael Gurevich, Anat Achiron

    出版事項 2022
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  7. 7
    Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis

    Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis 著者: Izhak Levi, Michael Gurevich, Gal Perlman, David Magalashvili, Shay Menascu, Noam Bar, Anastasia Godneva, Liron Zahavi, Danyel Chermon, Noa Kosower, Bat Chen Wolf, Gal Malka, Maya Lotan‐Pompan, Adina Weinberger, Erez Yirmiya, Daphna Rothschild, Sigal Leviatan, Avishag Tsur, Maria Didkin, Sapir Dreyer-Alster, Hen Eizikovitz, Yamit Titngi, Sue Mayost, Polina Sonis, Mark Dolev, Yael Stern, Anat Achiron, Eran Segal

    出版事項 2021
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: